NEW YORK (GenomeWeb News) – Life Technologies has struck a collaborative partnership with the Structural Genomics Consortium to develop and release 200 highly specific epigenetic recombinant antibodies, the company said today.
The partners have now released 58 of these antibodies, a move that SGC Director and CEO Aled Edwards said in a statement marks "the first step toward developing the defacto standard set of quality epigenetics antibodies that researchers can use for generations to come."
These recombinant antibodies are being released via Life Technologies' website, and on the open-access antibody database 1DegreeBio.org.
The SGC is an international effort to make genomic data publicly available for use in disease and drug research. It is comprised of a network of over 200 researchers from the University of Toronto and Oxford University, and from the pharmaceutical firms AbbVie (the research-based pharmaceutical business that is being spun out of Abbott), Eli Lilly, GlaxoSmithKline, Novartis, Pfizer, and Takeda.
The company said that these recombinant antibodies offer "a significant improvement" over antibodies currently available because they are renewable and validated for consistent performance across applications, including immunoprecipitation.
"The availability of high-quality research tools, such as Life Technologies' antibodies, will enable scientists to explore this completely new layer of biology and push the boundaries of our understanding of human disease, and facilitate the discovery of novel therapeutic targets," Life Technologies President and COO Mark Stevenson said.